dc.contributor.author | Cortes, J. E. | |
dc.contributor.author | Hochhaus, A. | |
dc.contributor.author | le Coutre, P. D. | |
dc.contributor.author | Rosti, G. | |
dc.contributor.author | Pinilla-Ibarz, J. | |
dc.contributor.author | Jabbour, E. | |
dc.contributor.author | Gillis, K. | |
dc.contributor.author | Woodman, R. C. | |
dc.contributor.author | Blakesley, R. E. | |
dc.contributor.author | Giles, F. J. | |
dc.contributor.author | Kantarjian, H. M. | |
dc.contributor.author | Baccarani, M. | |
dc.date.accessioned | 2018-09-20T16:04:10Z | |
dc.date.available | 2018-09-20T16:04:10Z | |
dc.date.issued | 2011-04-05 | |
dc.identifier.citation | Cortes, J. E. Hochhaus, A.; le Coutre, P. D.; Rosti, G.; Pinilla-Ibarz, J.; Jabbour, E.; Gillis, K.; Woodman, R. C.; Blakesley, R. E.; Giles, F. J.; Kantarjian, H. M.; Baccarani, M. (2011). Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib. Blood 117 (21), 5600-5606 | |
dc.identifier.issn | 0006-4971,1528-0020 | |
dc.identifier.uri | http://hdl.handle.net/10379/10921 | |
dc.description.abstract | Nilotinib has significant efficacy in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and in patients with CML-CP or CML in accelerated phase (CML-AP) after imatinib failure. We investigated the occurrence of cross-intolerance to nilotinib in imatinib-intolerant patients with CML. Only 1/75 (1%) patients with nonhematologic imatinib intolerance experienced a similar grade 3/4 adverse event (AE), and 3/75 (4%) experienced a similar persistent grade 2 nonhematologic AE on nilotinib. Only 7/40 (18%) patients with hematologic imatinib intolerance discontinued nilotinib, all because of grade 3/4 thrombocytopenia. Ninety percent of imatinib-intolerant patients with CML-CP who did not have complete hematologic response (CHR) at baseline (n = 52) achieved CHR on nilotinib. Nilotinib induced a major cytogenetic response in 66% and 41% of patients with imatinib-intolerant CML-CP and CML-AP (complete cytogenetic response in 51% and 30%), respectively. Minimal cross-intolerance was confirmed in patients with imatinib-intolerant CML. The favorable tolerability of nilotinib in patients with imatinib intolerance leads to alleviation of AE-related symptoms and significant and durable responses. In addition to its established clinical benefit in patients with newly diagnosed CML and those resistant to imatinib, nilotinib is effective and well-tolerated for long-term use in patients with imatinib intolerance. This study is registered at http://www.clinicaltrials.gov as NCT00471497 (Blood. 2011; 117(21): 5600-5606) | |
dc.publisher | American Society of Hematology | |
dc.relation.ispartof | Blood | |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 Ireland | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/3.0/ie/ | |
dc.subject | abl tyrosine kinase | |
dc.subject | chronic myelogenous leukemia | |
dc.subject | bcr-abl | |
dc.subject | inhibitor nilotinib | |
dc.subject | formerly amn107 | |
dc.subject | pdgf receptors | |
dc.subject | resistance | |
dc.subject | growth | |
dc.title | Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib | |
dc.type | Article | |
dc.identifier.doi | 10.1182/blood-2010-11-318949 | |
dc.local.publishedsource | http://www.bloodjournal.org/content/bloodjournal/117/21/5600.full.pdf | |
nui.item.downloads | 0 | |